Treatment strategies in the adjuvant and neoadjuvant setting

The introduction of checkpoint inhibitors and targeted therapy with kinase inhibitors revolutionized the treatment options for patients with advanced-stage melanoma. While there is already a lot of evidence for immunotherapy in the adjuvant setting, anti-PD-1 therapy also delivered convincing results in the neoadjuvant setting in a recent study. There are also interesting new findings on the mechanisms of immunotherapy resistance and the use of oncolytic viruses and therapeutic vaccinations.